Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer

Mise à jour : Il y a 4 ans
Référence : EUCTR2013-001653-27

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To evaluate whether treatment with targeted agents guided by high throughput molecular analyses (CGH array, next generation sequencing) improves overall progression-free survival as compared to standard maintenance therapy in patients with metastatic NSCLC.


Critère d'inclusion

  • Patients with metastatic non small cell lung cancer (NSCLC) in 1st line chemotherapy

Liens